Hofseth BioCare ASA (HBC.OL)
NOK 1.95
(0.0%)
NOK 1.95
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 29.87 Million NOK | -291.34% |
| 2022 | 28.51 Million NOK | 23.44% |
| 2021 | 23.09 Million NOK | -22.28% |
| 2020 | 29.72 Million NOK | 262.14% |
| 2019 | 8.2 Million NOK | -33.7% |
| 2018 | 12.37 Million NOK | -80.52% |
| 2017 | 63.54 Million NOK | 178.26% |
| 2016 | -81.2 Million NOK | -693.33% |
| 2015 | -10.23 Million NOK | -298.8% |
| 2014 | 5.14 Million NOK | -86.31% |
| 2013 | 37.62 Million NOK | 1732.54% |
| 2012 | 2.05 Million NOK | 184.74% |
| 2011 | 721 Thousand NOK | 321.64% |
| 2010 | 171 Thousand NOK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 3.23 Million NOK | 2570.84% |
| 2024 Q1 | -1.32 Million NOK | 95.65% |
| 2023 Q2 | 25.85 Million NOK | 647.37% |
| 2023 Q4 | -30.52 Million NOK | -292.33% |
| 2023 Q3 | 15.87 Million NOK | -38.62% |
| 2023 FY | -54.55 Million NOK | -291.34% |
| 2023 Q1 | 3.46 Million NOK | -42.15% |
| 2022 Q4 | 5.98 Million NOK | 4.13% |
| 2022 Q3 | 5.74 Million NOK | -29.03% |
| 2022 Q2 | 8.09 Million NOK | -6.91% |
| 2022 FY | 28.51 Million NOK | 23.44% |
| 2022 Q1 | 8.69 Million NOK | 69.46% |
| 2021 Q2 | 9.48 Million NOK | 12.28% |
| 2021 Q1 | 8.44 Million NOK | 32.39% |
| 2021 Q3 | 41 Thousand NOK | -99.57% |
| 2021 Q4 | 5.13 Million NOK | 12414.63% |
| 2021 FY | 23.09 Million NOK | -22.28% |
| 2020 FY | 29.72 Million NOK | 262.14% |
| 2020 Q1 | 12.28 Million NOK | 325.82% |
| 2020 Q3 | 3.41 Million NOK | -55.32% |
| 2020 Q2 | 7.64 Million NOK | -37.74% |
| 2020 Q4 | 6.37 Million NOK | 86.74% |
| 2019 Q4 | -5.43 Million NOK | -240.66% |
| 2019 Q2 | 6.01 Million NOK | 59.83% |
| 2019 Q1 | 3.76 Million NOK | -17.29% |
| 2019 Q3 | 3.86 Million NOK | -35.74% |
| 2019 FY | 8.2 Million NOK | -33.7% |
| 2018 Q2 | 2.97 Million NOK | 20.32% |
| 2018 FY | 12.37 Million NOK | -80.52% |
| 2018 Q1 | 2.47 Million NOK | -62.61% |
| 2018 Q4 | 4.55 Million NOK | 77.01% |
| 2018 Q3 | 2.57 Million NOK | -13.49% |
| 2017 Q3 | 6.95 Million NOK | 1155.42% |
| 2017 FY | 63.54 Million NOK | 178.26% |
| 2017 Q4 | 6.6 Million NOK | -5.02% |
| 2017 Q1 | 49.43 Million NOK | 1062.14% |
| 2017 Q2 | 554 Thousand NOK | -98.88% |
| 2016 Q4 | -5.13 Million NOK | 84.6% |
| 2016 FY | -81.2 Million NOK | -693.33% |
| 2016 Q2 | -35.16 Million NOK | -366.85% |
| 2016 Q1 | -7.53 Million NOK | -219.42% |
| 2016 Q3 | -33.37 Million NOK | 5.09% |
| 2015 Q3 | 503 Thousand NOK | 113.58% |
| 2015 Q4 | -2.35 Million NOK | -568.79% |
| 2015 FY | -10.23 Million NOK | -298.8% |
| 2015 Q1 | -4.68 Million NOK | 54.2% |
| 2015 Q2 | -3.7 Million NOK | 20.88% |
| 2014 FY | 5.14 Million NOK | -86.31% |
| 2014 Q4 | -10.21 Million NOK | -386.62% |
| 2014 Q3 | 3.56 Million NOK | 2.59% |
| 2014 Q2 | 3.47 Million NOK | -58.27% |
| 2014 Q1 | 8.32 Million NOK | -35.6% |
| 2013 Q1 | 4.89 Million NOK | 296.37% |
| 2013 Q2 | 4.98 Million NOK | 1.82% |
| 2013 Q3 | 14.8 Million NOK | 196.91% |
| 2013 Q4 | 12.93 Million NOK | -12.68% |
| 2013 FY | 37.62 Million NOK | 1732.54% |
| 2012 Q1 | -421.5 Thousand NOK | -168.12% |
| 2012 Q3 | 2.75 Million NOK | 5.02% |
| 2012 Q4 | -2.49 Million NOK | -190.7% |
| 2012 FY | 2.05 Million NOK | 184.74% |
| 2012 Q2 | 2.61 Million NOK | 721.28% |
| 2011 Q1 | 433.8 Thousand NOK | 389.06% |
| 2011 Q4 | 618.8 Thousand NOK | 555.0% |
| 2011 FY | 721 Thousand NOK | 321.64% |
| 2011 Q3 | -136 Thousand NOK | 30.61% |
| 2011 Q2 | -196 Thousand NOK | -145.18% |
| 2010 Q4 | 88.7 Thousand NOK | -20.52% |
| 2010 FY | 171 Thousand NOK | 0.0% |
| 2010 Q3 | 111.6 Thousand NOK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Arctic Bioscience AS | 9.77 Million NOK | -205.691% |
| Aqua Bio Technology ASA | 607.92 Thousand NOK | -4814.57% |
| ArcticZymes Technologies ASA | 113.01 Million NOK | 73.563% |
| BerGenBio ASA | 354 Thousand NOK | -8339.831% |
| PCI Biotech Holding ASA | 2.99 Million NOK | -899.231% |
| Thor Medical ASA | - NOK | -Infinity% |
| Ultimovacs ASA | -2.76 Million NOK | 1179.371% |